2017欧洲地区恶性肿瘤交流会LBA重磅消息科学研究前20名城在这儿了！ 。
摘 要：印度的 威罗菲尼。
梳理：汪汪狗兔来源于：恶性肿瘤新闻资讯2017 年欧洲地区肿瘤外科学好(ESMO)将于9月8-12日在葡萄牙费城举办。做为欧洲地区一年一度的恶性肿瘤盛会，重磅消息科学研究不可或缺，在其中LBA系列产品更为神密，称得上重磅消息中的楷模。2017 ESMO，LBA的前20大科学研究都是有哪一些？下边追随【手机微信咨询顾问：yaodaoyaofang】掌握详细信息 一起来看一一下吧！LBA1_PR - PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab after chemoradiation therapy (CRT) in patients with Stage III, locally advanced, unresectable NSCLC PACIFIC：一项部分晚中后期不能摘除的III期NSCLC病患者放化疗与放化疗（CRT）后Durvalumab的双盲实验、安慰剂对照III期科学研究LBA2_PR - Osimertinib vs SoC EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA) 奥希替尼VS SoC EGFR-TKI一线医治EGFRm的晚中后期NSCLC（FLAURA）LBA3_PR - MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer MONARCH 3: Abemaciclib医治HR / HER2-晚中后期乳腺癌病患者的原始治疗方法LBA4_PR - RANGE: a randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma PR - RANGE: 多西紫杉醇（DOC）协同/不协同雷莫芦单抗（RAM）医治铂不易治晚中后期或迁移扩散性尿路上皮癌的任意、双盲实验、安慰剂对照3期科学研究LBA5 - CheckMate 214: Efficacy and safety of nivolumab ipilimumab (N I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups CheckMate 214: nivolumab ipilimumab（N I）较为舒尼替尼（S）原始医治晚中后期或迁移扩散性肾细胞癌（mRCC）的治疗效果和安全防护特点，包含IMDC风险和PD-L1表述亚组LBA6_PR - COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma PR - COMBI-AD: 佐剂达拉非尼 曲美替尼在手术摘除的BRAF V600E / K基因突变III期黑色素瘤中的治疗效果LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600 melanoma at high risk for recurrence PR - BRIM8:一项佐剂威罗菲尼在手术彻底摘除、反复发风险高的BRAFV600 黑色素瘤病患者中的任意、双盲实验、安慰剂对照科学研究 LBA8_PR - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238) CheckMate 238：一项Ⅲ、Ⅳ期黑素瘤全切做完术后nivolumab（Nivo）较为ipilimumab（IPI）輔助医治的任意、双盲实验、3期实验LBA9 - Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICANCER-NeoPAL study UNICANCER-NeoPAL的分析结论：来曲唑协同palbociclib较为第三代有机化学治疗法药新辅助治疗luminal型乳腺癌的治疗效果LBA10_PR - Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER /HER2-negative early breast cancer (EBC) LORELEI的首要結果：一项新輔助来曲唑（LET）协同taselisib较为LET协同安慰剂效应（PLA）在ER / HER2呈阴性初期乳腺癌（EBC）的绝经期后病患者（pts）中的II期随机双盲科学研究LBA11 - Prognostic impact of Recurrence Score (RS), grade/Ki67 central pathological review, and anthracycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results 反复发得分、Ki67级别和含／没有蒽环类有机化学治疗法，针对临床医学相对高度风险HER（－）初期乳腺癌的远方和部分没病存活的愈后危害：WSG PlanB实验結果LBA12 - Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy 分子生物学剖析发觉合拼新輔助EGFR靶向治疗和化学治疗部分晚中后期三呈阴性乳腺癌的潜在性反复发标识物LBA13 - Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pem
bro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086 KEYNOTE-086：派姆单抗（pembro）对迁移扩散性三呈阴性乳腺癌（mTNBC）的治疗效果与恶性肿瘤侵润网织红细胞（TIL）水准的关联LBA14 - Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial TONIC：一项对于三呈阴性乳腺癌诱发医治后，行nivolumab的响应式II期任意、非对比临床试验LBA15 - SToRM: a clinical cohort to identify genetic variability related to metastatic phenotypes SToRM：评定与迁移蔓延基因型有关的遗传与变异的临床医学队列研究LBA16 - REGOMA: a randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients REGOMA:一项评定重反复性胶原纤维母细胞瘤病患者中瑞戈非尼活力的任意、多核心、对比的对外开放标识II期临床试验LBA17 - Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors 抗CC趋化因子蛋白激酶4（CCR4）抗原mogamulizumab（Moga）和nivolumab（Nivo）组成在晚中后期或迁移扩散性实体肿瘤病患者中的I期科学研究LBA18 - Efficacy of BMS-986016, a Monoclonal Antibody That Targets Lymphocyte Activation Gene-3 (LAG-3), in Combination With Nivolu
mab in Pts With Melanoma Who Progressed During Prior Anti–PD-1/PD-L1 Therapy (mel prior IO) in All-Comer and Biomarker-Enriched Populations BMS-986016，靶向治疗网织红细胞活性遗传基因-3（LAG-3）的单抗协同Nivolumab对此前抗PD-1 / PD-L1医治（Mel before IO）进度的黑色素瘤病患者在全能型和微生物标示聚集群中的作用LBA19 - A Phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC RET结合呈阳性NSCLC中RETi 原始病患者的RXDX-105（抗VEGFR的强力RET缓聚剂）1b期科学研究LBA20 - Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: first in human clinical trial 瘤内（IT）双链RNA（dsRNA）BO-112在恶变实体肿瘤中的安全性特点和免疫力分子生物学活力：第一次身体临床试验药道全世界，助推性命。印度的全世界海淘药店：印度的有威罗菲尼吗。
